Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High – What’s Next?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $45.00 and last traded at $44.50, with a volume of 34013 shares changing hands. The stock had previously closed at $43.92.

Analysts Set New Price Targets

Several research firms recently commented on KNSA. Citigroup raised their target price on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Finally, Wedbush upped their target price on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $52.33.

Kiniksa Pharmaceuticals International Stock Performance

The firm has a 50-day moving average price of $41.78 and a 200-day moving average price of $38.06. The stock has a market cap of $3.30 billion, a PE ratio of 96.71 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The company had revenue of $180.86 million for the quarter, compared to the consensus estimate of $166.64 million. During the same quarter in the prior year, the company posted ($0.18) EPS. Kiniksa Pharmaceuticals International’s revenue was up 61.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 12,470 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $41.24, for a total transaction of $514,262.80. Following the completion of the transaction, the chief operating officer owned 22,714 shares in the company, valued at $936,725.36. This trade represents a 35.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Mark Ragosa sold 42,841 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $41.49, for a total value of $1,777,473.09. Following the completion of the sale, the chief financial officer directly owned 31,086 shares of the company’s stock, valued at $1,289,758.14. The trade was a 57.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 135,548 shares of company stock valued at $5,675,604. Corporate insiders own 53.48% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds have recently modified their holdings of KNSA. USA Financial Formulas acquired a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at $32,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares during the last quarter. Quarry LP acquired a new stake in shares of Kiniksa Pharmaceuticals International in the third quarter worth $44,000. Osaic Holdings Inc. purchased a new stake in Kiniksa Pharmaceuticals International in the second quarter valued at $31,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 582.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock valued at $53,000 after buying an additional 1,159 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.